The type of drug resistance | Univariable analysis | Multivariable analysis | ||
---|---|---|---|---|
OR (95%CI) | P value | aOR (95%CI) | P value | |
Underweight group vs Normal weight group | Â | Â | Â | Â |
DR-TB | 0.96 (0.846–1.09) | 0.532 | 0.977 (0.86–1.111) | 0.726 |
MR-TB | 1.041 (0.893–1.215) | 0.606 | 1.056 (0.904–1.233) | 0.493 |
MDR-TB | 0.891 (0.672–1.182) | 0.424 | 0.928 (0.698–1.235) | 0.610 |
PDR-TB | 0.801 (0.614–1.044) | 0.101 | 0.804 (0.615–1.052) | 0.112 |
INH-related resistance | 0.994 (0.846–1.169) | 0.944 | 0.948 (0.746–1.203) | 0.659 |
RFP-related resistance | 0.91 (0.719–1.153) | 0.436 | 0.948 (0.746–1.203) | 0.659 |
SM-related resistance | 0.844 (0.726–0.982) | 0.028* | 0.869 (0.746–1.012) | 0.071 |
MR-TB (INH) | 1.347 (1.049–1.730) | 0.020* | 1.31 (1.017–1.686) | 0.037* |
INH + SM resistance | 0.754 (0.558–1.019) | 0.066 | 0.751 (0.554–1.018) | 0.065 |
INH + RFP + SM resistance | 0.834 (0.555–1.255) | 0.384 | 0.881 (0.585–1.328) | 0.546 |
Any INH + SM resistance | 0.818 (0.656–1.019) | 0.073 | 0.831 (0.665–1.039) | 0.105 |
Susceptible | Reference | Reference | Reference | Reference |
Overweight group vs Normal weight group | Â | Â | Â | Â |
DR-TB | 1.101 (0.849–1.428) | 0.467 | 1.082 (0.832–1.407) | 0.559 |
MR-TB | 0.879 (0.617–1.253) | 0.476 | 0.854 (0.596–1.225) | 0.391 |
MDR-TB | 1.603 (1.002–2.566) | 0.049* | 1.639 (1.02–2.633) | 0.041* |
PDR-TB | 1.299 (0.812–2.076) | 0.275 | 1.284 (0.8–2.06) | 0.300 |
INH-related resistance | 1.251 (0.912–1.717) | 0.165 | 1.248 (0.907–1.716) | 0.174 |
RFP-related resistance | 1.29 (0.833–1.997) | 0.253 | 1.271 (0.817–1.977) | 0.287 |
SM-related resistance | 1.234 (0.927–1.641) | 0.149 | 1.224 (0.916–1.636) | 0.171 |
MR-TB (INH) | 0.734 (0.374–1.443) | 0.371 | 0.736 (0.373–1.449) | 0.375 |
INH + SM resistance | 1.361 (0.82–2.26) | 0.234 | 1.36 (0.815–2.268) | 0.239 |
INH + RFP + SM resistance | 1.948 (1.061–3.577) | 0.032* | 2.113 (1.141–3.912) | 0.017* |
Any INH + SM resistance | 1.472 (1.013–2.14) | 0.043* | 1.483 (1.017–2.164) | 0.041* |
Susceptible | Reference | Reference | Reference | Reference |
Obese group vs Normal weight group | Â | Â | Â | Â |
DR-TB | 0.739 (0.374–1.46) | 0.384 | 0.741 (0.374–1.469) | 0.391 |
MR-TB | 1.658 (0.766–3.587) | 0.199 | 1.62 (0.747–3.516) | 0.222 |
MDR-TB | – | – | – | – |
PDR-TB | 1.653 (0.505–5.409) | 0.406 | 1.712 (0.52–5.637) | 0.377 |
INH-related resistance | 0.945 (0.372–2.399) | 0.905 | 0.943 (0.37–2.403) | 0.901 |
RFP-related resistance | – | – | – | – |
SM-related resistance | 0.639 (0.307–1.328) | 0.230 | 0.644 (0.308–1.347) | 0.243 |
MR-TB (INH) | 1.350 (0.325–5.607) | 0.679 | 1.304 (0.313–5.435) | 0.715 |
INH + SM resistance | 2.038 (0.622–6.678) | 0.240 | 2.089 (0.633–6.892) | 0.226 |
INH + RFP + SM resistance | – | – | – | – |
Any INH + SM resistance | 1.136 (0.348–3.709) | 0.833 | 1.148 (0.349–3.775) | 0.820 |
Susceptible | Reference | Reference | Reference | Reference |